Skip to main content
NASDAQ:MRTX

Mirati Therapeutics Competitors

$154.76
+1.58 (+1.03 %)
(As of 05/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$151.99
$157.47
50-Day Range
$144.00
$179.73
52-Week Range
$91.90
$249.42
Volume600,519 shs
Average Volume499,371 shs
Market Capitalization$7.96 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.64

Competitors

Mirati Therapeutics (NASDAQ:MRTX) Vs. BGNE, RPRX, GMAB, HZNP, CVAC, and CTLT

Should you be buying MRTX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Mirati Therapeutics, including BeiGene (BGNE), Royalty Pharma (RPRX), Genmab A/S (GMAB), Horizon Therapeutics Public (HZNP), CureVac (CVAC), and Catalent (CTLT).

Mirati Therapeutics (NASDAQ:MRTX) and BeiGene (NASDAQ:BGNE) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, risk, institutional ownership and dividends.

Valuation and Earnings

This table compares Mirati Therapeutics and BeiGene's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mirati Therapeutics$3.34 million2,383.49$-213,260,000.00($5.69)-27.20
BeiGene$428.21 million66.13$-948,630,000.00($15.80)-19.54

Mirati Therapeutics has higher earnings, but lower revenue than BeiGene. Mirati Therapeutics is trading at a lower price-to-earnings ratio than BeiGene, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

94.9% of Mirati Therapeutics shares are held by institutional investors. Comparatively, 60.7% of BeiGene shares are held by institutional investors. 4.1% of Mirati Therapeutics shares are held by insiders. Comparatively, 9.0% of BeiGene shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings for Mirati Therapeutics and BeiGene, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mirati Therapeutics141002.60
BeiGene21602.44

Mirati Therapeutics currently has a consensus price target of $225.2308, suggesting a potential upside of 45.54%. BeiGene has a consensus price target of $317.1250, suggesting a potential upside of 2.70%. Given Mirati Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Mirati Therapeutics is more favorable than BeiGene.

Profitability

This table compares Mirati Therapeutics and BeiGene's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mirati TherapeuticsN/A-60.01%-54.21%
BeiGene-569.22%-56.81%-39.93%

Risk & Volatility

Mirati Therapeutics has a beta of 1.64, meaning that its stock price is 64% more volatile than the S&P 500. Comparatively, BeiGene has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500.

Summary

Mirati Therapeutics beats BeiGene on 9 of the 14 factors compared between the two stocks.

Mirati Therapeutics (NASDAQ:MRTX) and Royalty Pharma (NASDAQ:RPRX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability and analyst recommendations.

Valuation & Earnings

This table compares Mirati Therapeutics and Royalty Pharma's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mirati Therapeutics$3.34 million2,383.49$-213,260,000.00($5.69)-27.20
Royalty PharmaN/AN/AN/AN/AN/A

Royalty Pharma has lower revenue, but higher earnings than Mirati Therapeutics.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Mirati Therapeutics and Royalty Pharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mirati Therapeutics141002.60
Royalty Pharma05402.44

Mirati Therapeutics currently has a consensus target price of $225.2308, indicating a potential upside of 45.54%. Royalty Pharma has a consensus target price of $51.8750, indicating a potential upside of 29.11%. Given Mirati Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Mirati Therapeutics is more favorable than Royalty Pharma.

Institutional & Insider Ownership

94.9% of Mirati Therapeutics shares are owned by institutional investors. Comparatively, 40.9% of Royalty Pharma shares are owned by institutional investors. 4.1% of Mirati Therapeutics shares are owned by company insiders. Comparatively, 2.5% of Royalty Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Mirati Therapeutics and Royalty Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mirati TherapeuticsN/A-60.01%-54.21%
Royalty PharmaN/AN/AN/A

Summary

Mirati Therapeutics beats Royalty Pharma on 6 of the 8 factors compared between the two stocks.

Genmab A/S (NASDAQ:GMAB) and Mirati Therapeutics (NASDAQ:MRTX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation.

Institutional and Insider Ownership

6.2% of Genmab A/S shares are owned by institutional investors. Comparatively, 94.9% of Mirati Therapeutics shares are owned by institutional investors. 4.1% of Mirati Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Genmab A/S and Mirati Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Genmab A/S24902.47
Mirati Therapeutics141002.60

Genmab A/S currently has a consensus target price of $41.5714, indicating a potential upside of 13.27%. Mirati Therapeutics has a consensus target price of $225.2308, indicating a potential upside of 45.54%. Given Mirati Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Mirati Therapeutics is more favorable than Genmab A/S.

Profitability

This table compares Genmab A/S and Mirati Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Genmab A/S50.99%34.40%30.67%
Mirati TherapeuticsN/A-60.01%-54.21%

Earnings & Valuation

This table compares Genmab A/S and Mirati Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genmab A/S$804.57 million29.92$324.68 million$0.5171.96
Mirati Therapeutics$3.34 million2,383.49$-213,260,000.00($5.69)-27.20

Genmab A/S has higher revenue and earnings than Mirati Therapeutics. Mirati Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Genmab A/S has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, Mirati Therapeutics has a beta of 1.64, suggesting that its stock price is 64% more volatile than the S&P 500.

Horizon Therapeutics Public (NASDAQ:HZNP) and Mirati Therapeutics (NASDAQ:MRTX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Institutional and Insider Ownership

88.6% of Horizon Therapeutics Public shares are owned by institutional investors. Comparatively, 94.9% of Mirati Therapeutics shares are owned by institutional investors. 4.3% of Horizon Therapeutics Public shares are owned by company insiders. Comparatively, 4.1% of Mirati Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Horizon Therapeutics Public and Mirati Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Horizon Therapeutics Public43.55%25.66%14.19%
Mirati TherapeuticsN/A-60.01%-54.21%

Valuation & Earnings

This table compares Horizon Therapeutics Public and Mirati Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Horizon Therapeutics Public$1.30 billion15.17$573.02 million$1.9445.23
Mirati Therapeutics$3.34 million2,383.49$-213,260,000.00($5.69)-27.20

Horizon Therapeutics Public has higher revenue and earnings than Mirati Therapeutics. Mirati Therapeutics is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Horizon Therapeutics Public and Mirati Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Horizon Therapeutics Public001103.00
Mirati Therapeutics141002.60

Horizon Therapeutics Public currently has a consensus price target of $111.3636, suggesting a potential upside of 26.92%. Mirati Therapeutics has a consensus price target of $225.2308, suggesting a potential upside of 45.54%. Given Mirati Therapeutics' higher probable upside, analysts clearly believe Mirati Therapeutics is more favorable than Horizon Therapeutics Public.

Volatility & Risk

Horizon Therapeutics Public has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Comparatively, Mirati Therapeutics has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500.

Summary

Horizon Therapeutics Public beats Mirati Therapeutics on 10 of the 14 factors compared between the two stocks.

CureVac (NASDAQ:CVAC) and Mirati Therapeutics (NASDAQ:MRTX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.

Insider and Institutional Ownership

4.3% of CureVac shares are held by institutional investors. Comparatively, 94.9% of Mirati Therapeutics shares are held by institutional investors. 4.1% of Mirati Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for CureVac and Mirati Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CureVac11302.40
Mirati Therapeutics141002.60

CureVac presently has a consensus target price of $58.3333, suggesting a potential downside of 43.01%. Mirati Therapeutics has a consensus target price of $225.2308, suggesting a potential upside of 45.54%. Given Mirati Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Mirati Therapeutics is more favorable than CureVac.

Profitability

This table compares CureVac and Mirati Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CureVacN/AN/AN/A
Mirati TherapeuticsN/A-60.01%-54.21%

Valuation & Earnings

This table compares CureVac and Mirati Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CureVacN/AN/AN/AN/AN/A
Mirati Therapeutics$3.34 million2,383.49$-213,260,000.00($5.69)-27.20

CureVac has higher earnings, but lower revenue than Mirati Therapeutics.

Summary

Mirati Therapeutics beats CureVac on 6 of the 8 factors compared between the two stocks.

Catalent (NYSE:CTLT) and Mirati Therapeutics (NASDAQ:MRTX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Institutional & Insider Ownership

97.8% of Catalent shares are owned by institutional investors. Comparatively, 94.9% of Mirati Therapeutics shares are owned by institutional investors. 1.0% of Catalent shares are owned by company insiders. Comparatively, 4.1% of Mirati Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Catalent and Mirati Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Catalent$3.09 billion5.53$173 million$1.8853.45
Mirati Therapeutics$3.34 million2,383.49$-213,260,000.00($5.69)-27.20

Catalent has higher revenue and earnings than Mirati Therapeutics. Mirati Therapeutics is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Catalent and Mirati Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Catalent9.25%14.20%4.83%
Mirati TherapeuticsN/A-60.01%-54.21%

Risk & Volatility

Catalent has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500. Comparatively, Mirati Therapeutics has a beta of 1.64, suggesting that its share price is 64% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Catalent and Mirati Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Catalent01702.88
Mirati Therapeutics141002.60

Catalent presently has a consensus price target of $125.1250, suggesting a potential upside of 24.53%. Mirati Therapeutics has a consensus price target of $225.2308, suggesting a potential upside of 45.54%. Given Mirati Therapeutics' higher possible upside, analysts plainly believe Mirati Therapeutics is more favorable than Catalent.

Summary

Catalent beats Mirati Therapeutics on 9 of the 14 factors compared between the two stocks.


Mirati Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BeiGene logo
BGNE
BeiGene
1.3$308.78+1.3%$28.32 billion$428.21 million-15.28Earnings Announcement
Analyst Upgrade
Insider Selling
Royalty Pharma logo
RPRX
Royalty Pharma
1.9$40.18+1.0%$24.39 billionN/A0.00Earnings Announcement
Genmab A/S logo
GMAB
Genmab A/S
1.4$36.70+1.0%$24.07 billion$804.57 million28.45
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.6$87.74+1.3%$19.72 billion$1.30 billion23.97Insider Selling
CureVac logo
CVAC
CureVac
0.7$102.35+8.2%$19.13 billionN/A0.00Gap Up
Catalent logo
CTLT
Catalent
1.7$100.48+1.0%$17.12 billion$3.09 billion64.00
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.9$33.95+5.4%$16.06 billion$3.07 billion-59.56Analyst Upgrade
Insider Buying
Analyst Revision
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$132.92+0.3%$15.62 billion$219.75 million-16.98
Zai Lab logo
ZLAB
Zai Lab
1.6$151.68+4.0%$14.36 billion$12.98 million-50.06Earnings Announcement
Analyst Revision
Gap Up
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.1$75.51+0.1%$13.80 billion$1.70 billion17.28Insider Selling
Grifols logo
GRFS
Grifols
1.3$18.38+1.4%$12.64 billion$5.71 billion16.41
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.3$72.54+1.5%$12.06 billion$2.32 billion59.95Upcoming Earnings
News Coverage
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.6$10.42+1.4%$11.38 billion$16.89 billion-2.83Insider Selling
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
1.9$178.16+1.3%$10.14 billion$2.16 billion56.20
Bausch Health Companies logo
BHC
Bausch Health Companies
1.9$28.15+0.8%$10.09 billion$8.60 billion-5.17
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.5$36.76+1.6%$9.47 billionN/A0.00Earnings Announcement
Analyst Report
Lockup Expiration
Analyst Revision
News Coverage
United Therapeutics logo
UTHR
United Therapeutics
1.7$193.77+0.9%$8.68 billion$1.45 billion18.33Analyst Report
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$50.72+2.4%$7.57 billion$40.56 million-14.87Analyst Report
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.7$106.71+0.3%$7.20 billion$103.71 million-24.31Analyst Upgrade
Gap Up
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$67.88+1.2%$7.07 billion$87.99 million-80.81
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.3$218.96+0.0%$6.86 billion$311.33 million-127.30
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$127.24+7.6%$6.84 billion$14.98 million-15.50Upcoming Earnings
Perrigo logo
PRGO
Perrigo
2.2$45.01+1.7%$6.01 billion$4.84 billion-750.04Earnings Announcement
Unusual Options Activity
Analyst Revision
Gap Down
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$72.51+1.9%$5.78 billion$380.83 million-9.27
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$92.80+1.2%$5.41 billion$66.51 million17.12
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$37.37+0.2%$5.27 billion$1.12 billion77.85Analyst Report
Allakos logo
ALLK
Allakos
1.7$97.94+1.0%$5.25 billionN/A-35.74Earnings Announcement
Insider Selling
Analyst Revision
News Coverage
Galapagos logo
GLPG
Galapagos
1.3$76.06+2.5%$4.98 billion$1.00 billion-11.52Analyst Report
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$34.24+6.1%$4.84 billion$150,000.00-16.15Earnings Announcement
Unusual Options Activity
Analyst Revision
I-Mab logo
IMAB
I-Mab
1.2$62.08+0.0%$4.49 billion$4.31 million-2.15
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$66.05+3.4%$4.30 billionN/A-5.38Earnings Announcement
Analyst Report
Analyst Revision
Schrödinger logo
SDGR
Schrödinger
1.6$59.02+1.1%$4.13 billion$85.54 million0.00Analyst Report
Analyst Revision
LEGN
Legend Biotech
1.3$31.02+2.2%$4.13 billion$64.39 million0.00
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.6$69.45+6.4%$4.06 billion$6.87 million-6.71
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$25.47+6.9%$3.79 billion$204.89 million-31.84High Trading Volume
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.64+2.1%$3.67 billionN/A-6.15
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$60.48+1.2%$3.67 billion$806.43 million-8.57Analyst Report
Alkermes logo
ALKS
Alkermes
1.2$22.24+0.9%$3.57 billion$1.17 billion-48.35Insider Selling
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.86+1.5%$3.44 billion$114.62 million-7.60Analyst Revision
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$115.73+0.0%$3.41 billionN/A-57.58Analyst Report
Insider Selling
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.22+2.9%$3.40 billion$339.08 million-12.34Analyst Report
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.5$54.95+1.1%$3.38 billion$117.91 million-11.15
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$68.28+3.4%$3.36 billionN/A-19.45Analyst Upgrade
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$58.50+0.2%$3.13 billion$1.11 billion18.81Analyst Report
Arvinas logo
ARVN
Arvinas
1.7$63.84+1.3%$3.13 billion$42.98 million-24.94
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$37.86+0.8%$3.07 billion$60,000.00-11.76Earnings Announcement
Analyst Upgrade
Analyst Revision
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$78.27+4.3%$2.83 billion$26.52 million-6.90
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.50+0.5%$2.77 billion$644.77 million-10.34Upcoming Earnings
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.3$61.46+0.8%$2.71 billion$421.03 million21.64Analyst Report
Insider Selling
High Trading Volume
Gap Down
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$38.39+0.3%$2.70 billion$306.98 million-5.49
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.